Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-046393
Filing Date
2023-09-05
Accepted
2023-09-05 16:14:58
Documents
53
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K asnd-20230630.htm   iXBRL 6-K 2244651
2 GRAPHIC img147637031_0.jpg GRAPHIC 24005
3 GRAPHIC img147637031_1.jpg GRAPHIC 87314
4 GRAPHIC img147637031_2.jpg GRAPHIC 44326
  Complete submission text file 0000950170-23-046393.txt   7681425

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT asnd-20230630_pre.xml EX-101.PRE 258347
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT asnd-20230630_def.xml EX-101.DEF 169624
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT asnd-20230630_lab.xml EX-101.LAB 359231
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT asnd-20230630.xsd EX-101.SCH 49322
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT asnd-20230630_cal.xml EX-101.CAL 43501
47 EXTRACTED XBRL INSTANCE DOCUMENT asnd-20230630_htm.xml XML 1531782
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 231235905
SIC: 2834 Pharmaceutical Preparations